Cadrenal Therapeutics, Inc. (CVKD) has shared an announcement.
Cadrenal Therapeutics has announced a significant milestone with the FDA’s Orphan Drug Designation for tecarfarin, a medication aimed at preventing life-threatening blood clots in patients with mechanical heart support devices. This development could be a game-changer for both patient health outcomes and Cadrenal’s market position. The designation also comes with a “safe harbor” provision, protecting the company from certain types of litigation regarding forward-looking statements in their press release.
See more data about CVKD stock on TipRanks’ Stock Analysis page.
